Showing results (31-40 of 117) with videos related to
Sort By:
Pageof 12
Psychopharmacology|September 27, 2015
Clinical safety and hypothalamic-pituitary-adrenal axis effects of the arginine vasopressin type 1B receptor antagonist ABT-436David A Katz, Wei Liu, Charles Locke, et al.Brain and Behavior|March 16, 2017
Hypothalamic-pituitary-adrenal axis and depression symptom effects of an arginine vasopressin type 1B receptor antagonist in a one-week randomized Phase 1b trialDavid A Katz, Charles Locke, Nicholas Greco, et al.Antiviral Therapy|January 10, 2015
A novel ritonavir paediatric powder formulation is bioequivalent to ritonavir oral solution with a similar food effectAhmed Hamed Salem, Yi-Lin Chiu, Joaquin M Valdes, et al.Computers in Biology and Medicine|July 27, 2025
Neuroinflammation and immune microenvironment alterations following heat stroke: A transcriptomic perspectiveKuan-Nien Chou, Xin-Jie Lu, Hsing-Fan Lai, et al.Clinical Pharmacology in Drug Development|April 9, 2024
Bioequivalence of Elagolix/Estradiol/Norethindrone Acetate Fixed-Dose Combination Product: Phase 1 Results in Healthy Pre- and Postmenopausal WomenMong-Jen Chen, Patrick Marroum, Yi-Lin Chiu, et al.Journal of Pediatric Gastroenterology and Nutrition|January 6, 2007
Pharmacokinetics and pharmacodynamics of lansoprazole in children 13 to 24 months old with gastroesophageal reflux diseaseMelvin B Heyman, Weijiang Zhang, Bidan Huang, et al.International Journal of Molecular Sciences|September 28, 2023
Elucidating the Associated Biological Function and Clinical Significance of RHOJ Expression in Urothelial CarcinomaXin-Jie Lu, Hsing-Fan Lai, Sheng-Cheng Wu, et al.Frontiers in Oncology|December 27, 2021
The Inhibitory Effects of 6-Thioguanine and 6-Mercaptopurine on the USP2a Target Fatty Acid Synthase in Human Submaxillary Carcinoma CellsChiao-Pei Cheng, Shu-Ting Liu, Yi-Lin Chiu, et al.Journal of Clinical Pharmacology|July 2, 2011
Pharmacokinetics and safety of the lopinavir/ritonavir tablet 500/125 mg twice daily coadministered with efavirenz in healthy adult participantsJuki Ng, Yi-Lin Chiu, Walid Awni, et al.British Journal of Clinical Pharmacology|November 13, 2013
The H3 antagonist ABT-288 is tolerated at significantly higher exposures in subjects with schizophrenia than in healthy volunteersAhmed A Othman, George Haig, Hana Florian, et al.Pageof 12